Cure.’s Post

🔬 From Scientist to Entrepreneur: Key Insights Are you a scientist thinking about venturing into entrepreneurship? Prof. Thomas Baumert through BaseLaunch, shares valuable advice on making this transition. His tips cover crucial areas such as protecting intellectual property and engaging with investors. 👉 Read the full article for all nine essential tips: https://lnkd.in/eRKD89wv #Biotech #Entrepreneurship #Innovation #Startups #BaseLaunch

Join B2DG's upcoming event on 04/23/24 to learn how investors evaluate successful startup companies. Gain insights into key business issues faced by new ventures, from concept to market. Learn the skills and tools required to start a new venture and how to drive the commercialization of your product. The event will use Melanoma Diagnostic as an example of patented technology, product validation, and a successful exit. Don't miss out on this opportunity to understand the vocabulary of investors and the management team. Register now at https://lnkd.in/g92Ryfwd #startups #investors #newventures #entrepreneurship #commercialization

1. Safi Biotherapeutics aims to manufacture inexpensive red blood cells to address blood shortages. 2. The startup has secured over $16 million from the U.S. Department of Defense and recently announced a $5 million seed funding round. 3. The company has not yet received FDA approval and faces extensive testing to ensure safety and effectiveness. 4. The American Red Cross reported a significant blood shortage, highlighting the urgent need for alternative solutions like lab-grown blood. 5. Safi's production begins with progenitor cells from stem cells, which are converted into red blood cells through a complex bioreactor process. 6. The goal is to reduce production costs from under $2,000 to below $500 per unit, comparable to donated blood prices. 7. Safi plans to scale its production significantly, aiming to manufacture over 1 million units annually within several years. 8. The company's CEO emphasizes the need to build a sustainable supply chain to alleviate blood access concerns for patients and doctors.

We are thrilled to announce the addition of Helmuth van Es to our Board! Leiden, The Netherlands, April 8, 2024. Cantoni announced its Board of Directors has been strengthened with biotech industry veteran Helmuth van Es Ph.D. Helmuth van Es has more than 30 years of experience in life sciences as an entrepreneurial scientist and C-suite biotech executive. He was a co-founder of Galapagos and four other therapeutic biotech companies, three of which are at clinical stage and was the former CEO of Citryll developing the NETosis inhibitor to clinical proof of concept stage. A total of €125M was raised into these four startups. Helmuth continues to serve on the Citryll Board of Directors, and previously served on the boards of Antabio, Spinnovation, Audion Therapeutics and Hifibio. His therapeutic area of expertise includes rheumatoid arthritis, lupus, hidradenitis supperativa, sensorineural hearing loss, viral infections such as dengue, drug resistant bacterial infections, oncology and more. “We are honoured to welcome Helmuth to the Board of Cantoni. His impressive track record in drug discovery and development adds significant value to the progression of Cantoni’s programmes”, says Managing Director of LEH, and Director of Cantoni, Rob Mayfield. “Cantoni is a pioneer in the Nicotinamide N-methyltransferase (NNMT) space with best in class inhibitors in preclinical development for lipid disorders and cancer, originating from Leiden University. This is an exciting example of high quality science with the clear potential to become future medicines for patients in need. I am excited to join the Cantoni Board and support the team to help advance its lead asset into the clinic and beyond" says Helmuth van Es. About Cantoni: Cantoni Therapeutics B.V. is a private pharmaceutical company based in Leiden, the Netherlands that is dedicated to the development and commercialization of NNMT inhibitors. NNMT is expressed in a number of tissues including the liver and is found in other tissues such as adipocytes. NNMT is an attractive drug target for metabolic syndrome and certain cancers where it is found to be overexpressed. Elevated NNMT activity is correlated with obesity, insulin resistance and blood glucose levels as well as tumor aggressiveness and is believed to promote cancer migration, invasion, and proliferation through epigenetic changes.   Cantoni was founded in 2020 by Libertatis Ergo Holding B.V. (LEH) and scientific founders Dr Matthijs van Haren and Professor Nathaniel Martin, both scientists with an impressive track-record in discovery and optimization of small molecule drug candidates. www.cantonitx.nl   About LEH: LEH is an independent seed investor in life science and health companies, which creates, supports and invests in startup and spinout companies connected to the activities of Leiden University, many of which are located on the Leiden Bio Science Park. www.libertatisergo.com Contact: Rob Mayfield: r.h.mayfield@bb.leidenuniv.nl

WHY? Why do you do - what you do? Why I am in Biotech? Why develops NanoTemper biophysical tools for drug discovery? My WHY is very personal. Privat. It is very emotional. It is about family. It is about fear. My big WHY Is cancer. Why have we founded a Biophysical Tools company? To support scientists to fight cancer. Because it's so personal, I've made this video for you. What is your WHY? #biotechnology #entrepreneurship #startup ————————— I am Philipp - founder, CEO & business angel. My bootstrapped company NanoTemper is a global leader for biophysical tools for biotech. Like my content? Click my name + follow + 🔔

🎙 We recently had the pleasure of interviewing Arby Leonian, CEO and co-founder of Thermaiscan! 🤝 Learn more about Thermaiscan's mission, challenges, needs, and exciting future milestones in this interview conducted by Dr Robin Vicken Ohannessian MD MPH PhD. 🤩 Don't miss out on this insightful discussion about their innovative startup! #Innovation #Startup #HealthTech #Thermaiscan #TechTalk #Vickino

WHY? Why do I work for NanoTemper? It’s because of our vision of „a world where every disease is treatable“. It's because of the exceptional #team Philipp Baaske and Stefan Duhr brought together. It's because of our culture that allows me to generate #impact 🚀. Being the "new kid on the block" I still feel overwhelmed by what #biotech 2024 is like. Especially when our fellow biochemistry PhDs dive into their area of expertise. Good brainfood while doing business 🧠.   Just today, I read The Rise of Biologics: Emerging Trends and Opportunities from CAS.org (1). What's about to happen towards fighting common diseases with Biologics is huge 😍! #biotech (1) https://lnkd.in/d6hj-jGf

Two words that describe Forbes' 100 #startups to watch:

The #biotech entrepreneurial journey can be equal parts frustrating, exhilarating, and rewarding. In the early stages, it's essential to keep an eye on scalability and lean on partners who can help you reach your next milestone quickly and cost-effectively. Our customers attest that RoosterBio can be a powerful resource for #advancedtherapy startups by providing: ✅ Scalable and economical raw materials to take you from bench to clinic ✅ Technical guidance along the way to optimize your chance of success ✅ Expert-led services to advance your research quickly and efficiently with reduced overhead cost Learn more: https://lnkd.in/eMGMeNV3 #advancedtherapies #regenerativemedicine #gotomarket #biotechinnovation #startup

How do innovators turn the impossible into reality in life sciences? Our latest blog post by Ali Divan, Ph.D. explores insights shared by Bill Rastetter at a recent San Diego BIO event cohosted by IQHQ, San Diego Squared and LaunchBio. Check it out: https://lnkd.in/eVGPTuUf #Innovation #LifeSciences #Biotech #Entrepreneurship #LaunchBio #buildingbetterbiotechs